Literature DB >> 27056988

Blood's 70th anniversary: arsenic--from poison pill to magic bullet.

James D Griffin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27056988      PMCID： PMC4825409          DOI： 10.1182/blood-2015-10-638650

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  12 in total

Review 1.  From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia.

Authors:  Sai-Juan Chen; Guang-Biao Zhou; Xiao-Wei Zhang; Jian-Hua Mao; Hugues de Thé; Zhu Chen
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

2.  In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.

Authors:  G Q Chen; J Zhu; X G Shi; J H Ni; H J Zhong; G Y Si; X L Jin; W Tang; X S Li; S M Xong; Z X Shen; G L Sun; J Ma; P Zhang; T D Zhang; C Gazin; T Naoe; S J Chen; Z Y Wang; Z Chen
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

3.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.

Authors:  Z X Shen; G Q Chen; J H Ni; X S Li; S M Xiong; Q Y Qiu; J Zhu; W Tang; G L Sun; K Q Yang; Y Chen; L Zhou; Z W Fang; Y T Wang; J Ma; P Zhang; T D Zhang; S J Chen; Z Chen; Z Y Wang
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

4.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.

Authors:  G Q Chen; X G Shi; W Tang; S M Xiong; J Zhu; X Cai; Z G Han; J H Ni; G Y Shi; P M Jia; M M Liu; K L He; C Niu; J Ma; P Zhang; T D Zhang; P Paul; T Naoe; K Kitamura; W Miller; S Waxman; Z Y Wang; H de The; S J Chen; Z Chen
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

Review 5.  Acute promyelocytic leukemia: from highly fatal to highly curable.

Authors:  Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2008-03-01       Impact factor: 22.113

6.  Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.

Authors:  S L Soignet; P Maslak; Z G Wang; S Jhanwar; E Calleja; L J Dardashti; D Corso; A DeBlasio; J Gabrilove; D A Scheinberg; P P Pandolfi; R P Warrell
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

7.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

Authors:  M E Huang; Y C Ye; S R Chen; J R Chai; J X Lu; L Zhoa; L J Gu; Z Y Wang
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

8.  Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid.

Authors:  T R Breitman; S E Selonick; S J Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

9.  A history of the use of arsenicals in man.

Authors:  D M Jolliffe
Journal:  J R Soc Med       Date:  1993-05       Impact factor: 18.000

Review 10.  Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.

Authors:  Guilherme Augusto Dos Santos; Lev Kats; Pier Paolo Pandolfi
Journal:  J Exp Med       Date:  2013-12-16       Impact factor: 14.307
View more
  2 in total

1.  ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia.

Authors:  Qingyi Tong; Huijuan You; Xintao Chen; Kongchao Wang; Weiguang Sun; Yufeng Pei; Xiaodan Zhao; Ming Yuan; Hucheng Zhu; Zengwei Luo; Yonghui Zhang
Journal:  Nucleic Acids Res       Date:  2018-04-20       Impact factor: 16.971

2.  Influences of Realgar-Indigo naturalis, A Traditional Chinese Medicine Formula, on the Main CYP450 Activities in Rats Using a Cocktail Method.

Authors:  Huan-Hua Xu; Fei-Ran Hao; Mei-Xi Wang; Si-Jia Ren; Ming Li; Hong-Ling Tan; Yu-Guang Wang; Xiang-Lin Tang; Cheng-Rong Xiao; Qian-De Liang; Yue Gao; Zeng-Chun Ma
Journal:  Evid Based Complement Alternat Med       Date:  2017-03-21       Impact factor: 2.629
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.